Stay updated on SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial
Sign up to get notified when there's something new on the SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial page.

Latest updates to the SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial page
- Check5 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check19 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check27 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check48 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check63 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed descriptions of a clinical trial for triple-negative breast cancer and the addition of new identifiers and collaborators related to the study.SummaryDifference22%
Stay in the know with updates to SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SafetyEfficacy SGN-LIV1A+Pembrolizumab in TNBC Clinical Trial page.